{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'hormonal contraceptive alone may', 'not be sufficient. In the absence of', 'clinical pharmacokinetic interaction', 'study data in IMPs with', 'demonstrated or suspected human', 'teratogenicity/fetotoxicity,', 'recommendation for use of', 'hormonal contraceptives should be', 'thoroughly justified by the sponsor.', 'Additional contraceptive methods,', 'including supplementary barrier', 'methods, may be considered.', 'Females of childbearing potential', 'are defined as:', 'not surgically (documented', 'hysterectomy, bilateral', 'oophorectomy, or bilateral', 'salpingectomy) or congenitally', 'sterile', 'not postmenopausal', 'Description of different birth control', 'methods', 'Highly effective birth control', 'methods:', 'Highly effective birth control', 'methods that can achieve a failure', 'rate of less than 1% per year when', 'used consistently and correctly are', 'considered. Such methods include:', 'Combined estrogen and', 'progestogen hormonal contraception', '(oral, intravaginal, transdermal)', 'associated with inhibition of', 'ovulation; these should be initiated', 'at least 7 days (for IMPs without', 'suspected', 'teratogenicity/genotoxicity): and 1', 'month (for IMPs potentially', 'teratogenic/genotoxic) before the', 'first dose of IMP.', 'Progestogen-only hormonal', 'contraception (oral, injectable,', 'implantable) associated with', 'inhibition of ovulation; these should', 'be initiated at least 7 days (for IMPs', '131']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'without suspected', 'teratogenicity/genotoxicity) and 1', 'month (for IMPs potentially', 'teratogenic/genotoxic) before the', 'first dose of IMP.', 'Intrauterine device and', 'intrauterine hormone-releasing', 'system need to be in place at least 2', 'months before screening.', 'Bilateral tubal occlusion', 'Vasectomized partner provided', 'he is the sole sexual partner and has', 'received medical assessment of the', 'surgical process.', 'Sexual abstinence is only', 'considered a highly effective', 'method if defined as refraining from', 'heterosexual intercourse in the', 'defined period. The reliability of', 'sexual abstinence needs to be', 'evaluated in relation to the duration', 'of the clinical study and the', 'preferred and usual lifestyle of the', 'patient.', 'Periodic abstinence (eg,', 'calendar, ovulation, symptothermal,', 'post-ovulation methods), declaration', 'of abstinence for the duration of a', 'study, and withdrawal are not', 'acceptable methods of contraception', '(according to the Medicines and', 'Healthcare Products Regulatory', 'Agency).', 'Acceptable birth control methods:', 'Acceptable birth control methods', 'that result in a failure rate of more', 'than 1% per year include:', 'progestogen-only oral hormonal', 'contraception for which the', 'inhibition of ovulation is not the', 'primary mode of action; male or', 'female condom with or without', 'spermicide; cap, diaphragm, or', 'sponge with spermicide. The', 'combination of male condom with', '132']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'either cap, diaphragm, or sponge', 'with spermicide (double barrier', 'methods) are also considered', 'acceptable but not highly effective', 'methods of birth control.', 'Unacceptable birth control methods:', 'Periodic abstinence (calendar,', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'interruptus), spermicides only, and', 'lactational amenorrhoea method', '(LAM) are not acceptable methods', 'of contraception. Female condom', 'and male condom should not be', 'used together.', 'Male contraception:', 'Male patients must always use a', 'condom, except in cases of no', 'genotoxicity; or no demonstrated or', 'suspected human', 'teratogenicity/fetotoxicity', 'Vasectomy:', 'Use of contraceptive methods', 'applies also to vasectomized men,', 'because of the risk associated with', 'transfer of a drug via seminal fluid.', 'Contraception for female partners of', 'male study participants:', 'Female partners (who are not', 'pregnant) of male study participants', 'must use contraception for non-', 'pregnant WOCBP until the end of', 'relevant systemic exposure in case', 'of IMPs with genotoxicity or IMPs', 'with no genotoxicity but', 'demonstrated or suspected human', 'teratogenicity/fetotoxicity.', 'Pregnancy tests in females of', 'childbearing potential:', '1. Conduct monthly pregnancy', 'testing from first dose of IMP', 'until last dose of IMP and', 'additional 30 days in case the', 'IMP does not have a marketing', 'authorization and has suspected', '133']\n\n###\n\n", "completion": "END"}